WuXi ATU Partners with Wugen to Accelerate NK Cell Therapy Development
WuXi ATU, the gene and cell therapy-focused CTDMO unit of WuXi Apptec (SHA: 603259, HKG:...
CAR-T
Ascentage Pharma’s Lisaftoclax Shows Promising Results in Phase I Trial for Non-Hodgkin Lymphoma
Suzhou-based Ascentage Pharma (HKG: 6855) announced the publication of Phase I clinical study results for...
Genscript’s CAR-T Therapy JNJ-4528 Demonstrates 100% Effective Rate in Long-Term Myeloma Study
Genscript Biotech Corporation (HKG: 1548), a leading China-based Contract Development and Manufacturing Organization (CDMO), has...